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Coronary lesion location
Left main artery 1
Left anterior descending 12
Right coronary artery 7
Left circumflex artery 4
Number of patients 13
Angiographic success rate 100%
MI/Cardiac death in-hospital, 1 yr 0
Stent diameter (mm) 3 0.6
Stent length (mm) 15 4.9
Number of lesions treated 24
Coronary lesion location
Left main artery 1
Left anterior descending 12
Right coronary artery 7
Number of stents 26
Angiographic follow-up 100%
Length of follow-up 325 128
Binary restenosis 7.4%
Target vessel revascularization 1/24 (4.1%)
Target lesion revascularization 1/26 (3.8%)
Conclusions: EES is associated with a very low incidence of instent stenosis and target
lesion revascularization in patients with TCAD. Further studies are needed to determine
whether PCI with EES could alter the long term outcome of patients with TCAD.
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Background: Nobori stent (Terumo Co., Tokyo Japan), is the new concept Drug Eluting
Stent which has unique bioabsorbable polymer (Poly-Lactic Acid) and the anti-
proliferative agent Biolimus A9. We investigated the safety and the efficacy of Nobori
stent comparing to Cypher stent in Japanese population by a single blinded 3:2
randomized trial and met the primary endpoint, non inferiority in TVF. This is the first
report of three year clinical follow up data of Nobori Biolimus Eluting stent compared to
Cypher Sirolimus Eluting stent in Japanese population.
Methods: This is the first multicenter single-blinded, 3:2 randomized clinical trial
comparing Nobori and Cypher in 335 patients (Nobori 198 : Cypher 137) in Japan.
Patients with single de novo up to two native coronary lesions were treated. The primary
endpoint was TVF (cardiac death, MI and TVR) rate at 9 months; late loss (LL) and
restenosis rate (RR) at 8 months were major secondary angiographic endpoints, while
MACE and stent thrombosis were major secondary safety endpoints. Duration of dual
antiplatelet therapy (DAPT) was also recorded for all patients.
Results: No significant difference between both patient backgrounds was found. TLR
free rate of Nobori was 98.8% at 2years and 98.3% at 3years. (Cypher 96.0% and 95.2%).
MACE free rate of Nobori was 94.1% at 2years and 92.9% at 3years. (Cypher 93.7% and
92.0%). TVF free rate of Nobori was 92.1% at 2years and 90.9% at 3years. (Cypher
93.7% and 91.1%). No definite or probable stent thrombosis according to ARC definition
were found in both groups.
Conclusions: In this first randomized clinical trial of Nobori and Cypher stent in
Japanese population, Nobori stent was found non-inferior to Cypher in TVF, the primary
endpoint. TLR free rate at 3 years of Nobori tended to be higher than that of Cypher and
the differences in TLR free rate between Nobori and Cypher at 2 years and 3years were
increased (no statistical significance). MACE and TVF free rate of both stents at three
years were comparable. Further long term follow-up up to 5years may suggest longer term
safety of Nobori Stent.
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Background: There are few studies comparing the long-term clinical outcomes of
patients (pts) with peri-procedural myocardial infarction (P-MI) with those without P-MI
following percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) in
real world clinical practice.
Methods: A total of 1119 pts underwent PCI with DESs between 2004 and 2010 were
enrolled (control group, n1006 pts and P-MI group, n113 pts). P-MI was defined as
major CK-MB elevation (3X the upper limit of normal [ULN]) after PCI.
Results: There were no significant differences between the two groups except P-MI
group was more elderly, had more female, longer procedure time, higher number of target
vessel and stents. At 6 month routine follow-up angiography, there was no significant
difference in mean diameter stenosis %, incidence of binary restenosis and late loss
between the two groups. Among the major in-hospital outcomes, cardiac death was higher
in P-MI group. At 2-year (follow-up, 89.1%), and the cumulative incidence of total death,
cardiac death and total major adverse cardiac events (MACEs) were higher in P-MI group,
where as repeat PCI including target lesion revascularization (TLR) and target vessel
revascularization (TVR). However, when in-hospital mortality was excluded, the major
clinical outcomes were not different between the two groups up to 2 years (table).
Conclusions: P-MI was mainly associated with in-hospital cardiac death following PCI
with DES in real world clinical practice. However, P-MI doesn’t seem to be an
independent predictor for adverse clinical outcomes for long-term period.
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direct stent implantation to stenting with predilation or provisional stenting in
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Background: Previous studies were performed to investigate whether a strategy of direct
stent implantation without pre-dilatation is associated with a reduced incidence of
restenosis, compared to conventional stenting with pre-dilatation. However, none of these
studies were performed in the drug-eluting stent era. Therefore the STRESSED (direct
Stenting To Reduce REStenosis in Stent Era with Drug elution) study was designed and
carried out.
Methods: A total of 600 patients with stable or unstable angina pectoris or a recent (30
days) myocardial infarction were randomized to direct stenting, stenting after pre-
dilatation or a provisional stenting strategy. Primary endpoint was the mean minimal
lumen diameter (MLD) at 9 months follow-up angiography. Secondary endpoints were
the clinical procedural success defined as angiographic success without major adverse
cardiac events (MACE) at 9 months and two years follow-up.
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Results:
Table:
Direct stenting
Conventional
stenting
Provisional
stenting p value
PCI success 194/196(99%) 199/201 (99%) 199/200 (99.5%) 0.874
Stent
implantation
192/196 (98.0%) 199/201 (99.0%) 155/200 (77.5%) 0.001
9 month
follow-up
QCA MLD, mm 2.12 0.58 2.17 0.67 1.99 0.69 0.059
MACE 18/192 (9.4%) 9/197 (4.6%) 17/197 (8.6%) 0.152
Conclusions: Direct drug-eluting stenting did not reduce restenosis, when compared tot
conventional DES stenting. Provisional stenting was associated with a higher rate of
restenosis, however, no differences was observed in the rate of MACE during 9-month
follow-up, The 2 year clinical follow-up will be presented at the conference.
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Background: In the drug-eluting-stent (DSE) era, the rate of in-stent restenosis (ISR)
was substantially decreased. Previous randomized trials have suggested that DES
implantation may be efficacious to decrease incidence of repeated ISR. The purpose of this
study was to assess the efficacy of DES implantation for the treatment of ISR after
bare-metal stent (BMS) or DES implantation.
Methods: A total of 120 consecutive patients who developed ISR was included in this
study. Angiographical follow-up was performed in 78 of 120 patients (BMS 67, DES 53).
We compared the angiographical restenosis rate between the patients who underwent
percutaneous coronary intervention (PCI) using DES (DES group) and the patients who
underwent PCI using balloon angioplasty (balloon group).
Results: Overall rate of re-ISR was significantly lower in DES group than in balloon
group (16% vs, 39%, p0.05). In the subset of patients with BMS restenosis (n41), rate
of re-ISR between DES group and POBA group (17% vs, 24%, pNS). On the other
hand, ISR patients after DES implantation (n37) showed significantly lower rate of
re-ISR in DES group than that in POBA group (17% vs, 53%, p0.05).
Conclusions: The efficacy of DES implantation for the treatment of ISR might be
affected by the index stent types.
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Background: The safety and efficacy of the first generation cobalt chromium
everolimus-eluting stent (EES) have been demonstrated in several trials. The PROMUS
Element (Boston Scientific, Natick, Massachusetts) stent is a new generation EES, made
of platinum chromium alloy with thin strut designed to improve radial strength,
radiopacity, vessel conformability, fracture resistance, side-branch access and deliverabil-
ity. We aim to compare the long-term safety and efficacy of this novel PtCr-EES with the
first generation cobalt chromium EES (CoCr-EES) in patients who received them.
Methods: We analyzed retrospectively 788 patients who received PtCr-EES(n378) or
CoCr-EES (n410) from our centre cardiovascular database. The primary endpoint was
the one-year composite major adverse cardiac events (MACE) that include cardiac death,
myocardial infarction, target vessel revascularization and stent thrombosis.
Results: The mean age of the cohort was 58.710.1 years with males constituting 82.7%.
Diabetes mellitus was present in 322 (40.0%) patients. The majority (63.1%) of the lesions
treated were of AHA/ACC Type B2/C. The mean lesion length in the 2 groups were
26.1412.19 mm (PtCr-EES) vs 24.1411.86 (CoCr-EES), p0.009 respectively; and
the stent length were 31.2714.38mm (PtCr-EES) vs 31.2314.61mm (CoCr-EES),
p0.96 respectively. At one year, the results were as follow:
CoCr-EES
(n 410)
PtCr-EES
(n378) p value
Death 9 (2.2%) 12(3.2%) 0.394
Myocardial infarction 16 (3.9%) 9 (2.4%) 0.223
TVR 11 (2.7%) 9 (2.4%) 0.788
MACE 24 (5.9%) 22 (5.8%) 0.984
Stent Thrombosis 8 (2.0%) 5 (1.3%) 0.489
Conclusions: Our study showed that PtCr-EES stent, when used in real-world popula-
tion, showed similar efficacy as the first generation EES at 1 year with no safety concerns
related to the novel stent material and design. The TVR rate is low at 3% for both
groups.
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Background: The aim of this registry is to evaluate the clinical performance of a new
generation thin strut bare metal stent (BMS) in a large patient population with
pre-specified subgroups in standard clinical care.
Methods: Between Apr 09, and Nov 11, 2010, 1’016 subjects presenting with de-novo
and restenotic coronary artery lesions were consecutively enrolled in this international,
multicentric ENERGY Registry using a new generation BMS (PRO-Kinetic Energy) in
48 sites in 10 countries. Safety endpoints were MACE at 6 and 12 month FUP. QoL
(EQ-5D) evaluation was performed in a subgroup for all FUP intervals. Pre-specified
subgroups were diabetes, acute myocardial infarction (AMI), small vessels and elderly
subjects ( 75 yrs).
Results: The biggest subgroup was presented by AMI with 46% followed by elderly
29%, small vessel 26% and diabetes 17%. 90.7 percent (922/1’016) follow up compliance
at twelve-month follow-up was achieved. Database not locked yet.
AMI N
470
Elderly N
297
Small
vessel N
251
Diabetes
N 168
Male 79% 65% 73% 77%
Age 63.6
13.3
80.30 4.2 68.2 12 68.7 11
Smoker 59% 45% 57% 61%
Diabetes 6% 19% 19% 100%
B2/C type
lesions
47% 45% 37% 38%
Average stent
length (mm)
16.6 4.9 15.5 4.4 16.1 4.8 15.4 3.8
Mean Stent
diameter
(mm)
3.2 0.5 3.1 0.5 2.7 0.4 3.1 0.4
MACE
hierarchical
6.2% 6.5% 9.2% 7.4%
Cardiac
Death
1.2% 1.8% 1.3% 1.4%
MI 1.4% 1.8% 2.6% 2.0%
clinically
driven TLR
3.6% 2.9% 5.2% 4.1%
MACE rates for all subgroups are not statistically significant different (p0.05).
Conclusions: This new generation BMS with very thin struts and passive coating shows
excellent results through all subgroups, also confirmed in low MACE rates for AMI,
elderly, small vessels and diabetic subjects. Utility of such modern BMS platforms are still
very relevant in the era of DES.
TCT-631
Abstract Withdrawn
TUESDAY, OCTOBER, 23, 8:00 AM–10:00 PMwww.jacc.tctabstracts2012.com
JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stents B183
P
O
ST
E
R
S
